Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
Status:
Recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide
Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus
in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+),
neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).